Type 2 diabetes is not a chronic progressive disease requiring ever-escalating medication — it is reversible in most patients through nutritional ketosis, and the Virta Health trial is the longest and largest RCT proving it at scale.
2
Serum saturated fatty acid levels are driven overwhelmingly by dietary carbohydrate intake via de novo lipogenesis, not by dietary saturated fat — 'you are what you eat' is wrong at the molecular level.
3
Palmitoleic acid (16:1 POA) is an emerging biomarker of individual carbohydrate tolerance: it rises with excess carbohydrate intake via SCD-1 activation and predicts future metabolic disease years before glucose climbs.
4
Sarah Hallberg, diagnosed with stage IV EGFR-mutant non-small cell lung cancer in 2017, describes a four-year journey through targeted therapy, chemo rotations, multi-organ failure, and remission — and how health inequity kills patients during the delays she barely survived.
Protocols
Concrete recipes — what, when, how much, and why
7 items
Therapeutic carbohydrate restriction as first-line T2D reversal
WhatReduce dietary carbohydrate to below the individual threshold for nutritional ketosis — typically below 30-50g net carbs per day — to eliminate the primary glucose substrate driving hyperinsulinemia and allow beta cell recovery.
WhenAt diagnosis of T2D or pre-diabetes. Hallberg argues it should also be considered at first detection of insulin resistance markers (elevated POA, elevated fasting insulin with normal glucose) before diagnosis.
DoseVirta trial: continuous remote support for at least 2 years, with 5-year data collection. Hallberg's clinic experience: most patients see significant glycemic improvement within weeks; medication deprescription within months; potential for full reversal over 1-3 years.
For whomType 2 diabetics on any medication including insulin. Pre-diabetics. Anyone with metabolic syndrome components. Particularly powerful for patients on multiple insulin-escalating medications who have not been offered lifestyle-first treatment.
WhyT2D is driven by carbohydrate intake above individual tolerance generating hyperinsulinemia. Removing the substrate eliminates the driver. Weight loss is a secondary benefit, not the mechanism.
CaveatsRequires rapid medication deprescription (especially sulfonylureas and insulin) to avoid hypoglycemia. Continuous medical supervision is non-negotiable during the transition. Long-standing T2D with significant beta cell loss may achieve dramatic improvement without full reversal.
Hallberg's Indiana University clinic opened as a carbohydrate-restricted program when this approach was highly controversial. She spent an entire summer meeting with every department at the medical center to prepare them for patients who would return with 'normal' lipids and no medications. The institutional amendment she proposed — that all metabolic disease patients should be offered the carbohydrate-restriction option — passed unanimously once physicians reviewed the physiology.
Mechanism
Restriction of dietary carbohydrate reduces postprandial glucose → reduces insulin secretion → reduces hepatic de novo lipogenesis → reduces VLDL output → reduces triglycerides. Simultaneously, lower insulin allows fat mobilization from adipose → free fatty acids → hepatic ketogenesis → ketone production for brain and muscle fuel.
We were seeing type 2 diabetes all of the time consistently daily, and you're right — we were pulling them off of insulin at rates that I could never have believed had I not been the physician who was taking care of these patients.
Also said
“This is you know, I mean I hate to be like over dramatic, but it truly is quite miraculous — for a disease that everyone thought was chronic and progressive — to see people recover from it.”— Hallberg's clinical framing of T2D reversal: not management, but recovery.
Medication deprescription in T2D — communicate early mortality risk of insulin
WhatWhen initiating insulin therapy in a T2D patient, explicitly state that insulin controls acute glucose risk but is associated with higher long-term mortality risk, and that the therapeutic goal is to reduce insulin requirement rather than titrate upward.
WhenAt every insulin initiation conversation, and re-evaluated at every visit.
DoseOngoing — track insulin dose as a health metric. A 5-fold reduction (e.g. 100 → 20 units/day) is a major clinical win even without full discontinuation.
For whomPhysicians managing T2D patients being escalated to insulin; patients already on insulin.
WhyPatients often interpret continued insulin use as treatment failure. Reframing insulin dose as a biomarker of disease burden allows them to understand that reduction is the goal.
CaveatsRapid reduction in insulin on a carbohydrate-restriction protocol requires tight monitoring to prevent hypoglycemia, especially with sulfonylureas which must often be stopped or halved on day one.
Hallberg: 'the mandatory discussion that needs to occur is: I'm going to give this insulin to you because your blood sugars are so high they could acutely kill you — but I just want you to know, you're more likely to die on insulin. That's the truth.' She argues that if physicians were required to deliver this framing at every insulin initiation, more would be motivated to offer carbohydrate restriction before escalation.
I just want you to know you're more likely to die on insulin. That's what we need to tell people. That's the truth.
POA / palmitoleic acid as early metabolic risk screen
WhatOrder a fatty acid panel including palmitoleic acid (C16:1 / POA) as part of early metabolic risk assessment, especially in patients with normal fasting glucose but clinical suspicion of insulin resistance.
WhenAt routine metabolic workup, especially in patients with elevated triglycerides, family history of T2D, truncal obesity, or any component of metabolic syndrome even with normal HbA1c.
For whomAnyone in the 'healthy' range on standard labs who has any metabolic syndrome component. The PANIC pediatric study and Netherlands cohort (POA at 50 predicting CRP at 70) support its use as a decades-ahead predictor.
WhyPOA reflects SCD-1 activity which is an independent marker of carbohydrate-driven de novo lipogenesis and abdominal adiposity. It rises before HbA1c, before frank hyperglycemia, and potentially before postprandial glucose elevation in some patients.
CaveatsPOA is not yet a standard clinical test and the exact threshold for 'elevated' varies by study. Attia notes it is tightly correlated with fasting triglycerides — patients with very elevated TGs almost certainly have elevated POA, but the test may catch risk earlier in the African-American population where TGs are often normal despite insulin resistance.
Hallberg envisions POA guiding personalized carbohydrate limits: a person who triggers elevated POA at 175g carbs/day gets a different recommendation than one who handles 300g. This precision metabolic phenotyping approach is the longer-term vision — not everyone needs strict ketogenic restriction, only those whose SCD-1 is activated at lower thresholds.
What if we could put a risk predictor like poa into wider use — okay, which would give a person their individual carbohydrate threshold? What if it didn't need to be as low — what if we caught them earlier in the disease process?
WhatFor non-smoker lung adenocarcinoma with EGFR mutation, the standard treatment is a tyrosine kinase inhibitor (TKI) such as osimertinib (Tagrisso). The third-generation TKIs cross the blood-brain barrier, addressing brain metastases common in this population.
WhenImmediately upon genomic profiling confirming EGFR mutation type (exon 19 deletion, exon 21 L858R, etc.). Full molecular profiling before treatment initiation is mandatory for treatment selection.
DoseTKIs are continuous oral daily therapy. Median time to resistance: 8-30 months depending on TKI generation and tumor burden. Hallberg was on osimertinib for years across her treatment arc.
For whomEGFR exon 19 deletion or L858R mutation confirmed by tissue or liquid biopsy. Both EGFR and ALK mutations in never-smokers warrant targeted therapy over chemotherapy as first-line.
WhyEGFR-mutant lung cancer is a molecularly distinct disease from smoking-related lung cancer. TKIs target the driver mutation directly, achieving responses (including complete radiographic response of small-volume disease) that chemotherapy does not.
CaveatsAll TKIs develop resistance — the cancer always returns. High primary tumor burden (e.g. 6 cm primary) resists complete response and is a source of ongoing mutation that drives resistance. Osimertinib has a better brain-penetration profile but is not curative.
Hallberg's strategy was to actively deplete tumor burden between TKI cycles rather than passively waiting for resistance. This included stereotactic radiation to the primary lung mass when TKI stopped shrinking it, multiple chemo agents rotated every 8 weeks at low dose to stay ahead of resistance mutations, and anti-estrogen therapy (lupron + fulvestrant + palbociclib) targeting a secondary mutation overlapping with breast cancer treatment.
I had decided that I do not accept being a sitting duck. Because what the cancer world then wants is for a patient like me to just sit and wait for the cancer to come back. And I couldn't accept that as a mother.
Also said
“The idea is what if we hit it with less, and then change it up all the time right, and this goes to the idea of beating the mutations before they can get you.”— The adaptive therapy philosophy Hallberg adopted — stay ahead of clonal resistance evolution rather than push one drug to failure.
Full genomic profiling on cancer recurrence biopsy — mandatory for clinical trial access
WhatWhen a cancer patient experiences recurrence, advocate aggressively for a core needle biopsy large enough to provide a complete genomics profile. Request this at the time of recurrence imaging, not weeks later.
WhenImmediately upon confirmation of recurrence via imaging. Do not wait for the oncologist to initiate — self-advocate if necessary.
For whomAny cancer patient experiencing recurrence, regardless of prior genomic profiling. Mutations evolve during treatment and the recurrent tumor may have new actionable alterations.
WhyClinical trial eligibility typically requires confirmed genomic mutation status from fresh tissue. A standard small biopsy may be inadequate. The delay Hallberg experienced (4 months from recurrence to treatment) was largely caused by difficulty obtaining adequate tissue for profiling while disease progressed rapidly.
CaveatsThis requires assertive self-advocacy within a system that may default to small biopsies or liquid biopsy alone. Hallberg notes that patients without medical literacy and specialist networks are likely dying in the same delays she barely survived.
Hallberg's four-month delay was not due to unavailability of treatment — it was because obtaining adequate tissue for a full genomics report required pushing against institutional inertia. By the time she started her clinical trial on December 30, she had bronchial compression and could not climb stairs without oxygen desaturation.
I had to advocate advocate the heck out of getting a biopsy done — a biopsy that would be enough tissue to make me eligible for a clinical trial — that would actually get me a full genomics report. I had to get almost obnoxious about it.
Pharmacogenetic testing before chemotherapy selection
WhatBefore selecting chemotherapy agents, test the patient's germline pharmacogenetics to identify drug-metabolizing enzyme mutations that could cause toxic drug accumulation at standard doses.
WhenBefore initiating any chemotherapy regimen, especially in patients with atypical prior responses or known sensitivity.
For whomAny cancer patient being considered for chemotherapy, particularly those with unusual reactions to prior agents or from populations with variable drug metabolism.
WhyHallberg developed atypical hemolytic uremic syndrome (aHUS) — a life-threatening multi-organ failure syndrome — after only 4 weeks on gemcitabine at very low dose due to a metabolizing enzyme mutation causing toxic accumulation.
CaveatsPharmacogenetic testing is not universally available or ordered. Physicians told Hallberg gemcitabine was a 'breeze'; she nearly died from it.
Hallberg's aHUS from gemcitabine: hemoglobin 6, platelets 23, liver failure, kidney failure, respiratory failure requiring ICU admission. Over 70% of aHUS cases result in death or permanent dialysis. She survived via plasmapheresis and eculizumab. The pharmacogenetic finding explained the otherwise inexplicable 4-week onset: her enzyme mutation caused toxic accumulation even at low dose, meaning other chemo agents remain safe for her.
It turns out I had a genetic mutation that didn't allow the gems are to break down. So I was getting toxic doses of this. And I was on a very low dose. But the thing is — that um — I couldn't get rid of it.
Reduce triglycerides via carbohydrate restriction, not dietary fat restriction
WhatIn patients with elevated fasting triglycerides (above 100 mg/dL by Hallberg's clinical threshold, or 150 by AHA standard), the primary dietary intervention is carbohydrate restriction — not fat restriction.
WhenAt any cardiovascular risk evaluation, metabolic syndrome assessment, or NAFLD workup.
DoseVolek's 2008 12-week study: triglycerides dropped from 211 to 104 mg/dL on low-carb vs. 187 to approximately 150 mg/dL on low-fat at matched calories.
For whomAny patient with elevated fasting triglycerides, NAFLD, or metabolic syndrome. Particularly impactful for patients who have been told to reduce dietary fat without improvement.
WhyTriglycerides are synthesized in the liver via DNL from dietary carbohydrate and exported in VLDL. Dietary fat is either oxidized or stored, not substantially converted to VLDL triglyceride in a carbohydrate-restricted state.
The Volk feeding study: at 84g saturated fat/day (ketogenic phase), serum saturated fat was actually higher in the low-fat high-carb arm than the high-fat low-carb arm. The mechanism is SCD-1 upregulation: carbohydrates → insulin → SREBP-1 → SCD-1 → palmitoleic acid → VLDL. Reducing dietary saturated fat while maintaining carbohydrate does not reduce serum saturated fat because the liver simply makes more via DNL.
Again, arguing against you are what you eat. The carbohydrate restricted group — we see a significant decrease down — whereas we do see a drop in the saturated fatty low saturated fatty acid intake group, but not nearly as much as we see with the carbohydrate restricted group.
What's new
Personal practice updates, fresh positions, predictions
6 items
88% of adult Americans are NOT in optimal metabolic health
~45 min
Analysis of NHANES data found that 88 percent of adult Americans fail at least one of the five metabolic syndrome criteria — meaning only 12 percent are in optimal metabolic health. Over 50 percent have diabetes or pre-diabetes.
Why this matters: The conventional conversation about metabolic disease focuses on the diagnosed minority. The NHANES finding reframes it as the near-universal condition — normal-glucose Americans in the non-diagnosed 50 percent are almost certainly already insulin-resistant.
Background
The five metabolic syndrome criteria are: blood pressure below 130/80, fasting glucose below 100, triglycerides below 150, HDL above 40 (men) or 50 (women), and absence of truncal obesity — all without medications.
Hallberg argues that the HbA1c threshold for diagnosis (6.5) is a crude lagging indicator — by the time someone crosses it, they have typically had insulin resistance for 5-10 years. Microvascular damage (retinal, erectile, peripheral nerve) is already underway during the pre-diabetic phase. Attia notes his practice uses CGM in non-diabetics specifically for this reason, holding patients to high standards of average glucose and excursion control.
88 of adult Americans are not in optimal metabolic health. And that is by looking at nhanes data and taking a look at the criteria for metabolic syndrome.
In Brittany Volk's controlled feeding study, participants consuming 84 grams of saturated fat per day (three times AHA guidelines) showed no rise in serum saturated fatty acids compared to participants on a low-fat high-carb arm — and the high-carb arm actually trended toward higher serum saturated fat.
Why this matters: Overturns the foundational premise that a high-saturated-fat diet raises blood saturated fat levels. The actual driver is carbohydrate intake driving de novo lipogenesis in the liver, not dietary fat composition.
Background
The Volk study used six feeding phases in an isocaloric design — same total calories but ratcheting carbohydrate from <50g/day to 346g/day across phases, with saturated fat inversely titrated from 84g to 32g.
The mechanism: dietary carbohydrate drives insulin secretion → insulin activates SREBP-1 in the liver → SREBP-1 upregulates SCD-1 (sterol-CoA desaturase) → SCD-1 converts palmitic acid (C16:0) into palmitoleic acid (C16:1) for packaging into VLDL and export. The liver is attempting to protect itself from excess glucose by converting it to fat and exporting it. Jeff Volek's 2008 12-week trial confirms: the low-carb high-saturated-fat arm showed a 12% relative reduction in serum saturated fat versus only 5% in the low-fat arm, despite consuming three times the dietary saturated fat.
When we have the very high saturated fat level, very low carbohydrate — and what's really interesting is what happens as we march along here down to c6 — it's actually the saturated fatty acid content is actually higher with the lower saturated fat intake.
Also said
“You are what you eat, right? We hear that still every day. Well, okay, if that's true, then when I consume a very high level of saturated fatty acids, why am I not seeing that in the blood in the serum?”— Hallberg's crisp reframing of the study's core finding against dietary dogma.
Palmitoleic acid (POA / 16:1) as a personalized carbohydrate-tolerance biomarker
~1 h 15 min
Palmitoleic acid, the product of SCD-1 converting palmitic acid, is an independent marker of triglyceridemia and abdominal adiposity. It rises when an individual exceeds their personal carbohydrate tolerance threshold, and predicts CRP levels and metabolic disease decades in advance — even in people with normal glucose.
Why this matters: Proposes a molecular early-warning system for insulin resistance that is earlier, more specific, and more personalized than HbA1c. The PANIC study tracked POA levels in childhood and found health consequences decades later. A Netherlands study correlated POA at age 50 with CRP at age 70.
Background
SCD-1 (sterol-CoA desaturase-1, also called delta-9 desaturase) adds a double bond to C16:0 palmitic acid to produce C16:1 palmitoleic acid. SCD-1 activity is an independent marker of triglyceridemia and abdominal adiposity.
Hallberg envisions POA as a population screening tool that could tell an individual their personal carbohydrate threshold before disease manifests. Someone caught early might only need to stay below 175g carbs per day rather than pursue strict ketogenic restriction, because the beta cells are not yet exhausted. Attia connects this to CGM use in non-diabetics: both tools aim to catch the pre-pathological window when intervention is highest leverage.
What if we could put a risk predictor like poa into wider use — okay, which would give a person their individual carbohydrate threshold? What if it didn't need to be as low — what if we caught them earlier in the disease process?
Also said
“Sterol coa desaturase is actually an independent marker of triglyceridemia and abdominal adiposity. So in other words, an independent marker of all those things that go along with insulin resistance.”— The biochemical basis for POA as a metabolic risk marker independent of glucose.
T2D reversal is possible even after years on high-dose insulin — beta cell dormancy not death
~1 h 40 min
Some patients on 100+ units of insulin per day achieve normal glycemia on carbohydrate restriction, eventually come entirely off insulin after years — suggesting beta cells were dormant rather than dead. The limiting factor is whether functioning beta cells remain, which predicts who can eventually tolerate reintroduced carbohydrates.
Why this matters: Challenges the conventional model that type 2 diabetes is irreversibly progressive. The practical implication: even a five-fold reduction in insulin requirement is a massive health improvement even if complete discontinuation is not possible.
Background
Standard diabetes management escalates insulin over time, which drives weight gain and hyperinsulinemia. Hallberg argues the goal should be reducing insulin to the minimum effective dose, not titrating upward for glycemic control.
Hallberg: 'there's a big difference between taking a hundred units of insulin a day to achieve normal glycemia and taking 20 units of insulin a day to achieve normal glycemia.' Patients on carbohydrate restriction who cannot fully come off insulin within months sometimes do so years later, suggesting slow beta cell regeneration or recovery from glucotoxicity. The bariatric surgery literature mirrors this: rapid post-surgical T2D resolution before significant weight loss confirms the mechanism is metabolic, not purely mechanical.
I mean, the fact that people were on the incredibly high dose of insulin, okay, starting on a very low carbohydrate diet — and then they got better right away okay — a lot of the changes swift, but they couldn't get off insulin. And it was just years went by, right, and they're just staying on this much lower level of insulin, and then all of a sudden they come off of it.
Non-smoker lung cancer is a growing, under-researched epidemic hitting thin, healthy women
~2 h 20 min
12-14% of all lung cancer patients are non-smokers. Among this group, adenocarcinoma driven by EGFR or ALK mutations predominates, it strikes younger women disproportionately, and the causal pathway remains almost entirely uninvestigated despite lung cancer being the leading cancer killer of both sexes.
Why this matters: The cultural association of lung cancer with smoking creates a blind spot in research, prevention, and clinical index of suspicion. A non-smoking woman who is fit, thin, and healthy is the demographic most likely to be missed until the tumor is a 6-centimeter mass with brain metastases.
Background
Hallberg, a physician who never smoked, was diagnosed at 46 with stage IV EGFR exon 19 deletion lung adenocarcinoma presenting with a brain tumor that caused a speech seizure.
The two main genomic subtypes in never-smokers are EGFR-driven (most common) and ALK-positive. Both respond to targeted tyrosine kinase inhibitors (TKIs), which can clear small-volume disease dramatically in weeks — but always develop resistance, typically within 8-30 months depending on the TKI generation. Hallberg's critical insight: the standard-of-care posture of 'wait on a TKI until it fails, then switch' is passive. Her 'hit it with less, change it up constantly' approach with her physician aimed to stay ahead of resistance mutations.
Non-smoking lung cancer is growing at scary rates. It's being diagnosed and it hits people in their prime. It's growing rapidly, especially in young women. It happens in caucasian and asian women predominantly, and the interesting thing is most of the people that it impacts are thin and in shape or athletes.
Health equity and cancer recurrence: the system nearly abandons patients when disease returns
~3 h 10 min
Hallberg — a physician with insurance, specialist networks, and medical literacy — experienced a four-month delay between her cancer recurrence (September 2020) and starting a clinical trial (December 30). She progressed so much she could not climb stairs without desaturating. She argues most patients without her advantages die in that window.
Why this matters: Exposes a structural gap in oncology: initial diagnosis triggers intensive navigation support, but recurrence is often met with institutional inertia. Hallberg calls this 'the system gives up on you' and it amplifies the already severe disparity in cancer outcomes by privilege, education, and means.
Hallberg's four-month delay required advocacy she describes as 'almost obnoxious': demanding a large enough biopsy for full genomics profiling (not the standard small sample), fighting for a clinical trial slot, and navigating her own deterioration while doing so. She had tens of thousands of dollars in out-of-pocket expenses and personal physician relationships to call at any hour. She contrasts this with the reality that healthcare bankruptcy is the leading source of personal bankruptcy in the US, and a cancer recurrence for someone without her resources is frequently terminal by delay alone.
I had to advocate advocate the heck out of getting a biopsy done — a biopsy that would be enough tissue to make me eligible for a clinical trial — that would actually get me a full genomics report. I mean, that wasn't going to happen. I had to get almost obnoxious about it.
Recommendations
Products, supplements, and tools mentioned in the episode
3 items
The Art and Science of Low Carbohydrate Living by Stephen Phinney and Jeff Volek
Book
The foundational textbook on the physiology of nutritional ketosis that Attia describes having more highlights and post-its than any book he owns. Hallberg read it as the evidence base before opening her carbohydrate-restriction clinic.
Attia: 'I might have been one of the first people to get a copy of the book that he and Jeff wrote in 2011... which I still have. It might have more highlights and post-its in it than any book I own, because I think, like you, I was going through — this can't be something — there's something so counterintuitive to this that I need to read this over and over and over again to make sure I get it.'
The art and science book, which I have, it might have more highlights and post-its in it than any book I own — because I think like you I was kind of going through this — this can't be something — there's something so counterintuitive to this that I need to read this over and over and over again to make sure I get it.
Continuous glucose monitor (CGM) for metabolic phenotyping in non-diabetics
Tool
Attia describes using CGM in non-diabetics as a precision tool to catch early metabolic dysfunction that HbA1c misses — tracking average glucose, postprandial excursions, and time-in-range to a higher standard than population norms.
The clinical rationale: HbA1c of 5.6 is 'normal' but may represent average glucose of 110-115 with frequent postprandial spikes to 160+. CGM captures those spikes. In the Hallberg framework, CGM alongside POA measurement would allow metabolic phenotyping years before diagnosis.
We use CGM a lot, so continuous glucose monitoring is kind of — we don't, you know, non-diabetics are wearing CGM like it's no tomorrow in our practice — because of that exact reason. We're basically holding them to a very high standard of average glucose and high excursions and all these sorts of things.
Cancer patient self-advocacy: demand adequate-tissue biopsy and full genomic profiling at recurrence
Practice
Hallberg urges every cancer patient experiencing recurrence to become 'almost obnoxious' in demanding a core tissue biopsy large enough for complete genomic sequencing — and to request this immediately at recurrence diagnosis, not weeks later when disease progression may make trial eligibility impossible.
Hallberg built a framework from her recurrence experience: (1) demand adequate tissue for genomics the day recurrence is confirmed; (2) ask your oncologist about clinical trials immediately; (3) seek pharmacogenetic testing before chemo selection; (4) find a physician who shares the 'actively fight it' posture. The health equity implication: this advocacy required physician contacts, medical literacy to read genomic reports, and financial resources most patients lack.
vs alternatives
Liquid biopsy (circulating tumor DNA) is faster and less invasive but often lacks the tissue depth needed for full genomic profiling or clinical trial enrollment. Both should be done simultaneously at recurrence.
Has anyone else been in this situation? And I find out it happens all of the time. It seems that we have a really good system when someone is diagnosed with cancer — they get a cancer navigator, they get all these things — but when that cancer comes back it's kind of like the system seems to give up on you.
Virta Health — remote type 2 diabetes reversal program
Service Sponsored · disclosed
Virta Health delivers a remote continuous-care model combining nutritional ketosis with 24/7 physician and health coach support for type 2 diabetics. The Virta 2-year trial showed 60% of participants reduced HbA1c to below diabetic threshold; 5-year data was being collected at time of recording.
DisclosureHallberg is a founding clinical leader of Virta; Attia is a small investor and former advisor. Explicit conflict disclosed by Attia at the outset.
Founded by Sarah Hallberg, Dr. Stephen Phinney, and Dr. Jeff Volek. The trial is described by Hallberg as the longest and largest study of nutritional ketosis for T2D reversal. The pre-diabetes paper (with 2-year data) published on the day of this recording showed significant glycemic improvement in HbA1c 5.7-6.4 patients using remote support to achieve nutritional ketosis.
We're at the tail end of our five-year data collection of the longest and largest trial looking at nutritional ketosis as a means of reversing type 2 diabetes and pre-diabetes.
Lines worth pulling out — contrarian, specific, or perfectly phrased
5 items
88 of adult Americans are not in optimal metabolic health. I mean let me say that again — 88 of adult Americans are not in optimal metabolic health.
The single most alarming statistic in the episode — reframes metabolic disease from a minority problem to the near-universal American health state.
I felt like a legal drug dealer. I got really lucky here — I like to say a lot of my pivots are pivoted on anger, right? Pivots in my career. And I was really angry at what was happening on the primary care level.
Hallberg's characterization of the moment she abandoned standard-of-care dietary advice — the physician-as-drug-dealer framing captures the harm of a treatment model that chronically escalates medication without treating the root cause.
I just want you to know you're more likely to die on insulin. That's what we need to tell people. That's the truth.
The most direct clinical statement in the episode — the mandatory consent framing Hallberg believes physicians are ethically required to deliver at every insulin initiation.
I do not accept being a sitting duck. Because what the cancer world then wants is for a patient like me to just sit and wait for the cancer to come back. Right — that's what you're doing — you know it's coming back, there's no question about it, and you are just waiting. And I couldn't accept that as a mother.
The philosophical declaration that drove Hallberg's aggressive multi-agent cancer treatment strategy — and the patient-as-active-agent framing she wants other cancer patients to adopt.
At that point I decided — you can live feeling sorry for yourself and of all the things that you're going to lose — or you can go out and live. And your kids are going to be better for it.
The inflection point on a plane to the Aspen fellowship — the moment Hallberg describes choosing to live fully with a terminal diagnosis rather than retreat. The most emotionally resonant moment in the episode.
Sign in to share feedback
Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.
Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.
Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.
